Inhaler Negative-Pressure Amplification for Consistent Powder Deagglomeration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dry powder inhalers (DPIs) face challenges in achieving consistent delivery of fine particle fraction (FPF) independent of user inhalation effort, leading to variable drug deposition in the lungs versus the mouth and throat, and lack an efficient deagglomeration system that can be incorporated into various inhaler types.
Innovation Solution
A negative pressure amplification apparatus that transforms patient inhalation energy into a higher-magnitude negative pressure, enhancing deagglomeration efficiency by positioning the medicament in a reduced-pressure zone within the airflow, allowing for consistent delivery of fine particles and minimizing throat deposition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If carrier-based formulations are used to bulk up volume for accurate metering, then dose metering accuracy is improved, but deagglomeration efficiency deteriorates due to difficulty in separating fine API particles from coarse carrier particles
Solution Approach 1:
The patent applies preliminary action by creating a reduced-pressure zone before the medicament to pre-accelerate the airflow. This preliminary acceleration of air allows for more effective deagglomeration of the carrier-based formulation when it reaches the throat region, thereby improving deagglomeration efficiency while maintaining the benefits of carrier-based metering accuracy.
Solution Approach 2:
The patent introduces a new dimension to the airflow dynamics by creating a reduced-pressure zone that accelerates airflow in the direction toward the patient's throat. This dimensional change in pressure distribution enables enhanced deagglomeration forces to act on the carrier particles, improving the separation of fine API particles from coarse carrier particles without compromising metering accuracy.
2Reliability
If fine API particles are delivered to reach deep lung deposition, then therapeutic efficacy is improved, but mouth and throat deposition increases causing unwanted side effects
Solution Approach 1:
The patent applies local quality by creating a specific reduced-pressure zone at a particular location in the airflow path (before the medicament). This localized pressure modification accelerates airflow specifically in the region where deagglomeration occurs, enabling better control over particle trajectory. The result is improved fine particle delivery to the lungs while reducing unwanted deposition in the mouth and throat.
Solution Approach 2:
The patent effectively creates a copied or replicated low-pressure environment similar to what would be found in high-performance inhalers, but adapts it for use with carrier-based formulations. By replicating the beneficial low-pressure zone effect, the system achieves enhanced deagglomeration and improved particle delivery characteristics without requiring complete redesign of the inhaler architecture.
3Device complexity
If patient inhalation energy is used to power the inhaler, then device simplicity is improved, but delivery consistency deteriorates due to variability in user inhalation strength
Solution Approach 1:
The patent applies parameter changes by modifying the pressure distribution parameter within the inhaler device. By creating a reduced-pressure zone that pre-accelerates airflow, the system changes the operating parameters of the airflow-medicament interaction. This parameter modification compensates for variations in patient inhalation strength, delivering more consistent fine particle fractions across different users while maintaining device simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The apparatus achieves a higher and more consistent FPF, reducing throat deposition and enhancing patient compliance by ensuring uniform drug delivery across varying inhalation strengths.
Implementation Method 1
The first amplifier chamber is configured to establish, in response to fluid being drawn from the apparatus outlet, a first primary fluid flow from the first primary inlet to the first outlet, and to create a first reduced-pressure zone of fluid at the first amplifier inlet
Implementation Method 2
the first amplifier chamber is configured to generate a pressure drop between the first outlet and the first amplifier inlet, such that in response to fluid being drawn from the apparatus outlet by an outlet negative pressure, the first reduced-pressure zone of fluid at the first amplifier inlet experiences a first inlet negative pressure that is greater in magnitude than the outlet negative pressure
Data Source
AI summary
A negative pressure amplifier apparatus comprises a first amplifier chamber comprising a first amplifier inlet, a first primary inlet, and a first outlet. The first outlet forms, or is in fluid connection with, an apparatus outlet. The first amplifier chamber is configured to establish, in response to fluid being drawn from the apparatus outlet, a first primary fluid flow from the first primary inlet to the first outlet, and to create a first reduced-pressure zone of fluid at the first amplifier inlet, such that a first fluid flow is drawn through the first amplifier inlet into the first reduced-pressure zone. The first amplifier inlet is positioned downstream of the first primary inlet, such that in use, the first fluid flow is introduced to the first reduced-pressure zone downstream of the first primary inlet. An inhaler apparatus comprising the negative pressure amplification apparatus is also provided.